



**Vivimed**

Date:13/02/2015

To

BSE Limited  
Listing Department  
P.J.Towers,Dalal Street,  
Mumbai – 400001

**BSE - Scripe Code : 532660**

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on 13<sup>TH</sup> February, 2015, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchanges, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended 31<sup>ST</sup> December,2014 attached herewith;

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

**For VIVIMED LABS LTD**

  
**SANTOSH VARALWAR**  
**MANAGING DIRECTOR & CEO**



**Vivimed Labs Ltd (Head Office)**

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, T.S. 500 007, India

T+91 (0) 40-2717 6005/6 F+91 (0) 40-2715 0599

[info@vivimedlabs.com](mailto:info@vivimedlabs.com) [www.vivimedlabs.com](http://www.vivimedlabs.com)



**VIVIMED LABS LIMITED**  
**CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS ENDED DEC '31' ST 2014**

Sl. No.	Particulars	Quarter Ended				9 Months Ended		Previous Year ended 31.03.2014 FY 14
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013		₹ in Lacs
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	34,370.89	31,363.86	33,526.56	102,388.40	98,265.98	135,083.30	
	(b) Other Operating Income	98.62	315.71	50.77	724.11	431.09	821.51	
	<b>Total Income From Operations (Net)</b>	<b>34,469.51</b>	<b>31,679.58</b>	<b>33,577.33</b>	<b>103,112.50</b>	<b>98,697.07</b>	<b>135,904.81</b>	
	a. Cost of Raw Materials Consumed	17,292.61	16,718.48	17,476.65	52,772.58	47,127.55	66,370.82	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(1,516.56)	(1,917.53)	(1,489.44)	(4,883.41)	2,456.53	(738.38)	
	d. Employee Benefit Expenses	4,780.18	4,225.10	4,494.47	13,721.67	11,845.89	17,206.48	
	e. Depreciation and Amortisation Expenses	1,843.10	1,653.82	1,693.98	5,147.06	4,896.66	6,611.62	
	f. Other Expenditure	7,886.57	7,474.68	7,735.54	24,301.97	21,784.70	31,739.01	
2	<b>Total Expenses</b>	<b>30,285.90</b>	<b>28,154.54</b>	<b>29,911.20</b>	<b>91,059.87</b>	<b>88,111.33</b>	<b>121,189.55</b>	
3	<b>Profit / (loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>4,183.61</b>	<b>3,525.04</b>	<b>3,666.13</b>	<b>12,052.63</b>	<b>10,585.74</b>	<b>14,715.26</b>	
4	Other Income							
5	<b>Profit / (loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>4,183.61</b>	<b>3,525.04</b>	<b>3,666.13</b>	<b>12,052.63</b>	<b>10,585.74</b>	<b>14,715.26</b>	
6	Finance Costs	1,937.23	1,968.75	1,564.84	5,933.68	4,265.60	6,029.10	
7	<b>Profit / (loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>2,246.38</b>	<b>1,556.29</b>	<b>2,101.29</b>	<b>6,118.95</b>	<b>6,320.14</b>	<b>8,686.16</b>	
8	Exceptional Items							
9	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>2,246.38</b>	<b>1,556.29</b>	<b>2,101.29</b>	<b>6,118.95</b>	<b>6,320.14</b>	<b>8,686.16</b>	
10	Tax Expenses	190.28	(84.79)	202.48	708.73	784.91	2,046.76	
11	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>2,056.09</b>	<b>1,641.07</b>	<b>1,898.81</b>	<b>5,410.21</b>	<b>5,535.23</b>	<b>6,639.41</b>	
12	<b>Extraordinary Items (net of tax expenses Rs.....lacs)</b>							
13	<b>Net Profit / Loss for period (11 - 12)</b>	<b>2,056.09</b>	<b>1,641.07</b>	<b>1,898.81</b>	<b>5,410.21</b>	<b>5,535.23</b>	<b>6,639.41</b>	
14	Share of Profit / (Loss) of associates							
15	Minority Interest							
16	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>2,056.09</b>	<b>1,641.07</b>	<b>1,898.81</b>	<b>5,410.21</b>	<b>5,535.23</b>	<b>6,639.41</b>	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)							
	(a) Basic	12.69	10.13	11.72	33.39	34.16	40.97	
	(b) Diluted	12.69	10.13	11.72	33.39	34.16	40.97	

1. The above Consolidated Unaudited Financial Results for the quarter ended & 9 Months ended December '31st 2014 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> February 2015

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octant's Nobel Labs Private Limited, (v) Vivimed Labs (Alachua) Pvt Limited (vi) Finsso Pharma Pvt Limited, (vii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain, (iv) Holiday International Limited UK & (v) Uquija Mexico S.A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

6. This quarter is the balancing figure of the YTD and the reported for last quarters.

7. Depreciation has been calculated basing on the provisions of the companies Act 2013

For VIVIMED LABS LIMITED

Place : Hyderabad  
Date : 13.02.2015

(SANTOSH JAGALWAR)  
MANAGING DIRECTOR & CEO





**VIVIMED LABS LIMITED**

**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

Particulars	3 Months Ended			9 Months ENDED		For the Year ended
	31.12.2014 (Unaudited)	30.09.2014 (Unaudited)	31.12.2013 (Unaudited)	31.12.2014 (Unaudited)	31.12.2013 (Unaudited)	31-03-2014 (Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a.Speciality Chemicals Business	10,925.98	9,866.70	10,741.09	29,754.34	30,512.52	41,431.92
b. Pharma Business	23,444.91	21,497.16	22,785.47	72,634.06	67,753.46	93,651.38
<b>Total</b>	<b>34,370.89</b>	<b>31,363.86</b>	<b>33,526.56</b>	<b>102,388.40</b>	<b>98,265.98</b>	<b>135,083.30</b>
Less, Inter Segment Revenue						
<b>Net sales / Income from Operations</b>	<b>34,370.89</b>	<b>31,363.86</b>	<b>33,526.56</b>	<b>102,388.40</b>	<b>98,265.98</b>	<b>135,083.30</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a.Speciality Chemicals Business	2,679.88	2,351.05	2,204.71	6,741.85	5,817.05	8,261.30
b. Pharma Business	1,503.73	1,173.99	1,461.41	5,310.79	4,768.70	6,453.96
<b>Total</b>	<b>4,183.61</b>	<b>3,525.04</b>	<b>3,666.13</b>	<b>12,052.64</b>	<b>10,585.75</b>	<b>14,715.26</b>
Less: 1. Interest	1,937.23	1,968.75	1,564.84	5,933.68	4,265.60	6,029.10
2. Other Un-allocable Expenditure			-			
3. Un-allocable Income			-			
<b>Total Profit Before Tax</b>	<b>2,246.38</b>	<b>1,556.29</b>	<b>2,101.29</b>	<b>6,118.95</b>	<b>6,320.14</b>	<b>8,686.16</b>
<b>3. Capital Employed</b>						
a.Speciality Chemicals Business	80,202.21	79,112.06	82,619.78	80,202.21	82,619.78	80,029.16
b. Pharma Business	62,269.98	64,002.71	63,246.47	62,269.98	63,246.47	67,372.76
<b>Total</b>	<b>142,472.19</b>	<b>143,114.77</b>	<b>145,866.25</b>	<b>142,472.19</b>	<b>145,866.25</b>	<b>147,401.92</b>

₹ in Lacs

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO



Place : Hyderabad

Date : 13.02.2015



**VIVIMED LABS LIMITED**  
**STANDALONE FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS ENDED DEC 2014**

Sl. No.	Particulars	Quarter Ended			9 Months Ended			Previous Year ended 31.03.2014 FY 14
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013		
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	10,527.52	9,573.18	10,339.97	30,373.54	30,418.34	43,199.35	
	(b) Other Operating Income	58.24	40.34	58.09	96.68	82.97	154.99	
	<b>Total Income From Operations (Net)</b>	<b>10,585.76</b>	<b>9,613.52</b>	<b>10,398.05</b>	<b>30,470.22</b>	<b>30,501.31</b>	<b>43,354.34</b>	
	a. Cost of Raw Materials Consumed	6,712.00	5,678.17	5,665.69	19,261.89	16,774.99	23,605.69	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(2,048.74)	(1,602.79)	(67.30)	(5,518.20)	375.79	(140.95)	
	d. Employee Benefit Expenses	624.01	830.03	636.21	2,003.62	1,767.82	1,983.25	
	e. Depreciation and Amortisation Expenses	663.71	451.62	456.00	1,563.49	1,351.64	1,806.35	
	f. Other Expenditure	2,404.14	2,190.93	1,748.11	6,775.33	4,520.18	7,784.86	
2	<b>Total Expenses</b>	<b>8,355.12</b>	<b>7,547.97</b>	<b>8,438.71</b>	<b>24,086.13</b>	<b>24,790.43</b>	<b>35,039.12</b>	
3	<b>Profit / (loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>2,230.64</b>	<b>2,065.55</b>	<b>1,959.34</b>	<b>6,384.09</b>	<b>5,710.88</b>	<b>8,315.12</b>	
4	Other Income							
5	<b>Profit / (loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>2,230.64</b>	<b>2,065.55</b>	<b>1,959.34</b>	<b>6,384.09</b>	<b>5,710.88</b>	<b>8,315.12</b>	
6	Finance Costs	1,714.03	1,491.92	1,093.64	4,633.55	2,941.74	4,434.39	
7	<b>Profit / (loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>516.61</b>	<b>573.63</b>	<b>865.70</b>	<b>1,750.54</b>	<b>2,769.14</b>	<b>3,880.73</b>	
8	Exceptional items							
9	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>516.61</b>	<b>573.63</b>	<b>865.70</b>	<b>1,750.54</b>	<b>2,769.14</b>	<b>3,880.73</b>	
10	Tax Expenses	103.32	136.31	173.14	416.79	553.83	1,217.81	
11	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>413.29</b>	<b>437.32</b>	<b>692.56</b>	<b>1,333.75</b>	<b>2,215.31</b>	<b>2,662.92</b>	
12	Extraordinary items (net of tax expenses Rs.....lacs)							
13	<b>Net Profit / Loss for period (11 - 12)</b>	<b>413.29</b>	<b>437.32</b>	<b>692.56</b>	<b>1,333.75</b>	<b>2,215.31</b>	<b>2,662.92</b>	
14	Share of Profit / (loss) of associates							
15	Minority Interest							
16	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (loss) of Associates (13 - 14 - 15)</b>	<b>413.29</b>	<b>437.32</b>	<b>692.56</b>	<b>1,333.75</b>	<b>2,215.31</b>	<b>2,662.92</b>	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary items) [of Rs. 10/- each] (not annualised)							
	(a) Basic	2.55	2.70	4.27	8.23	13.67	16.43	
	(b) Diluted	2.55	2.70	4.27	8.23	13.67	16.43	

1. The above Standalone Unaudited Financial Results for the Quarter ended & 9 months ended December 31<sup>st</sup> 2014 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> February, 2015

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Speciality Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

5. This quarter is the balancing figure of the YTD and the reported for last quarters.

6. Depreciation has been calculated basing on the provisions of the companies Act 2013

Place : Hyderabad  
Date : 13.02.2015

For VIVIMED LABS LIMITED  
(SANTOSH KARNALWARI)  
MANAGING DIRECTOR & CEO





**VIVIMED LABS LIMITED**

**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

₹ in Lacs

Particulars	3 Months Ended			TILL DATE	TILL DATE	YEAR ENDED
	31.12.2014 (Unaudited)	30.09.2014 (Unaudited)	31.12.2013 (Unaudited)	31.12.2014 (Unaudited)	31.12.2013 (Unaudited)	31-03-2014 (Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	8,060.31	7,914.34	8,511.31	24,074.34	24,671.80	35,112.23
b. Pharma Business	2,467.21	1,658.84	1,828.66	6,299.20	5,746.54	8,087.12
<b>Total</b>	<b>10,527.52</b>	<b>9,573.18</b>	<b>10,339.97</b>	<b>30,373.54</b>	<b>30,418.34</b>	<b>43,199.35</b>
Less, Inter Segment Revenue		-				
<b>Net sales / Income from Operations</b>	<b>10,527.52</b>	<b>9,573.18</b>	<b>10,339.97</b>	<b>30,373.54</b>	<b>30,418.34</b>	<b>43,199.35</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a. Speciality Chemicals Business	1,873.78	1,736.68	1,724.02	5,270.86	4,823.38	6,772.07
b. Pharma Business	356.86	328.87	235.32	1,113.23	887.50	1,543.05
<b>Total</b>	<b>2,230.64</b>	<b>2,065.55</b>	<b>1,959.35</b>	<b>6,384.09</b>	<b>5,710.88</b>	<b>8,315.12</b>
Less: 1. Interest	1,714.02	1,491.92	1,093.64	4,633.55	2,941.74	4,434.39
2. Other Un-allocable Expenditure		-				
3. Un-allocable Income		-				
<b>Total Profit Before Tax</b>	<b>516.61</b>	<b>573.63</b>	<b>865.70</b>	<b>1,750.54</b>	<b>2,769.14</b>	<b>3,880.73</b>
<b>3. Capital Employed</b>						
a. Speciality Chemicals Business	77,390.74	76,294.65	81,486.10	77,390.74	81,486.10	79,866.87
b. Pharma Business	29,567.82	29,108.61	21,440.14	29,567.82	21,440.14	29,180.79
<b>Total</b>	<b>106,958.56</b>	<b>105,403.27</b>	<b>102,926.24</b>	<b>106,958.56</b>	<b>102,926.24</b>	<b>109,047.66</b>

Place : Hyderabad  
Date : 13.02.2015

For VIVIMED LABS LIMITED  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



Part II					
Select Information for the Quarter and Year Ended 31/12/2014					
SL.No	Particulars	Quarter ended 31/12/2014	Quarter ended 30/09/2014	Quarter ended 31/12/2013	Year ended 31/03/2014
A	<b>PARTICULARS OF SHAREHOLDING</b>				
	Public Shareholding				
	Number of Shares	10031058	10026058	10074058	10026058
	Percentage of Shareholding	61.91%	61.87%	62.17%	61.87%
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	4079645	3110455	2482455	2482455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	66.09%	50.35%	40.50%	40.18%
	Percentage of shares (as a % of the total share capital of the company)	25.18%	19.20%	15.32%	15.32%
	(b) Non-encumbered				
	Number of Shares	2093080	3067270	3647270	3695270
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	33.91%	49.65%	59.50%	59.82%
	Percentage of shares (as a % of the total share capital of the company)	12.91%	18.93%	22.51%	22.81%

#### Investor's Complaints

Sl.no	Particulars	3 months ended 31/12/2014
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

To  
The Board of Directors  
**M/s. VIVIMED LABS LIMITED**  
Hyderabad

**Limited Review Report for the quarter ended 31 st December 2014**

We have reviewed the accompanying statement of unaudited financial results of **M/s. Vivimed Labs Limited** for the quarter ended 31<sup>st</sup> December 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed; or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants



Partner  
Kund Vijayrao Joshi  
M.No. 024784

Place: Hyderabad  
Date : 13<sup>th</sup> February 2015